Final Update Summary: Breast Cancer: Medication Use to Reduce Risk - US Preventive Services Task Force

Final Update Summary: Breast Cancer: Medication Use to Reduce Risk - US Preventive Services Task Force

Final Recommendation Statement: Medication Use to Reduce Risk of Breast Cancer

Final Recommendation Statement: Medication Use to Reduce Risk of Breast Cancer The U.S. Preventive Services Task Force released today a final recommendation statement on medication use to reduce risk of breast cancer. The Task Force found that some women at increased risk of breast cancer can benefit from risk-reducing medications. However, women who are not at increased risk should not take these medications. To view the recommendation, the evidence on which it is based, and a summary for clinicians, please go here. The final recommendation statement can also be found in the September 3, 2019 online issue of JAMA. The Final Recommendation Statement Is Available

FINAL RECOMMENDATION SUMMARY See the full statement

Population Recommendation Grade Women at increased risk for breast cancer The USPSTF recommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects. B Women not at increased risk for breast cancer The USPSTF recommends against the routine use of risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, in women who are not at increased risk for breast cancer. D

WHY THIS MATTERS

"There are medications available that can help some women prevent breast cancer, but they are not for everyone,” says Task Force member Michael J. Barry, M.D. “For women who are at increased risk for breast cancer, these medications can be beneficial and reduce their risk.”

WHERE WE ARE IN THE PROCESS

Draft Research Plan Final Research Plan Draft Recommendation / Draft Evidence Review  Final Recommendation / Evidence Summary